Nie Yuanhua, Zhao Zhiqiang, Chen Minxue, Ma Fulin, Fan Yong, Kang Yingxin, Kang Boxiong, Wang Chen
Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China.
Oncol Lett. 2021 Feb;21(2):107. doi: 10.3892/ol.2020.12368. Epub 2020 Dec 10.
Pancreatic cancer has a low survival rate globally. Anillin (ANLN) is involved in the pathogenesis of pancreatic cancer (PC). The present study used databases and reverse transcription-quantitative PCR to investigate the association between ANLN expression, clinical variables and the survival rate of patients with pancreatic cancer. Gene expression of ANLN in normal and cancer tissues was analyzed using data from The Cancer Genome Atlas, Oncomine and Gene Expression database of Normal and Tumor tissues 2 and ANOVA, and the association between ANLN mRNA expression and ANLN genovariation was analyzed using cBioPortal. The association between ANLN expression and the survival, clinical, pathological and prognostic characteristics of PC was analyzed using Kaplan-Meier (K-M) survival analysis, Kruskal Wallis and Mann Whitney-U tests, and logistic and Cox regression models. Gene Set Enrichment Analysis (GSEA) revealed the molecular pathways underpinning ANLN function in PC. Overexpression of ANLN was observed in PC cells (normal vs. tumor, P<0.01) and tissues (normal vs. tumor, P=0.008). Enhanced ANLN expression was associated with high tumor grade (grade 1 vs. grade 3, odds ratio: 5.662, P<0.001). However, ANLN expression was not associated with other clinical features (all P>0.05). K-M analysis suggested that increased ANLN expression was associated with poor survival (P=0.002). Univariate and multivariate analysis revealed the ANLN is an independent prognostic factor for PC (P<0.001). GSEA demonstrated the p53, cell cycle, DNA replication, mismatch repair, nucleotide excision repair and PC pathways were associated with low expression of ANLN. Overall, ANLN is more highly expressed in PC compared with in normal tissue, and is associated with poor differentiation. The expression of ANLN may be a novel prognostic marker of poor survival. Finally, ANLN exert its functions in PC through the p53, cell cycle, DNA replication, mismatch repair and nucleotide excision repair and pathways.
胰腺癌在全球范围内生存率较低。锚蛋白（ANLN）参与胰腺癌（PC）的发病机制。本研究利用数据库和逆转录定量PCR来探究ANLN表达、临床变量与胰腺癌患者生存率之间的关联。使用来自癌症基因组图谱（The Cancer Genome Atlas）、Oncomine以及正常与肿瘤组织基因表达数据库2的数据和方差分析（ANOVA）分析正常组织和癌组织中ANLN的基因表达，并使用cBioPortal分析ANLN mRNA表达与ANLN基因变异之间的关联。使用Kaplan-Meier（K-M）生存分析、Kruskal Wallis和Mann Whitney-U检验以及逻辑回归和Cox回归模型分析ANLN表达与PC的生存、临床、病理和预后特征之间的关联。基因集富集分析（GSEA）揭示了PC中ANLN功能所依据的分子途径。在PC细胞（正常细胞与肿瘤细胞，P<0.01）和组织（正常组织与肿瘤组织，P=0.008）中观察到ANLN过表达。ANLN表达增强与高肿瘤分级相关（1级与3级，优势比：5.662，P<0.001）。然而，ANLN表达与其他临床特征无关（所有P>0.05）。K-M分析表明，ANLN表达增加与较差的生存率相关（P=0.002）。单因素和多因素分析显示ANLN是PC的独立预后因素（P<0.001）。GSEA表明p53、细胞周期、DNA复制、错配修复、核苷酸切除修复和PC途径与ANLN低表达相关。总体而言，与正常组织相比，ANLN在PC中表达更高，且与低分化相关。ANLN的表达可能是生存率较差的一种新的预后标志物。最后，ANLN通过p53、细胞周期、DNA复制、错配修复和核苷酸切除修复及途径在PC中发挥其功能。
